Aumolertinib plus bevacizumab for untreated advanced NSCLC with EGFR sensitive mutation

Aumolertinib plus bevacizumab for untreated advanced NSCLC with EGFR sensitive mutation

BackgroundAumolertinib is a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) with proven efficacy and safety for untreated non-small-cell lung cancer (NSCLC) patients with EGFR sensitizing mutations (EGFRm) in China. The progression-free survival (PFS) imp...

Full description

Saved in:
Bibliographic Details
Main Authors: Lingping Kong, Lina Peng, Xue Yang, Qing Ma, Linlin Zhang, Xia Liu, Diansheng Zhong, Fanlu Meng
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Oncology
Subjects:
aumolertinib
bevacizumab
EGFR-TKI
non-small cell lung cancer
progression-free survival
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1595812/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2025.1595812/full

Similar Items